Australian bio-tech giant CSL has posted a 63 per cent rise in full-year profit to $1.15 billion.

Foreign exchange movements helped the company's bottom line, as well as the savings made from its failed bid for US plasma company Talecris.

CSL's chief executive, Brian McNamee, says the company could make about $300 million from sales of the swine flu vaccine this financial year.

"We have a significant contract with the Australian government and others, so I think heading towards 300's a reasonable estimate, I mean we still have to make it, we still have to get the yields, there's some technical matters here, but I think that's not an unreasonable ball park," he said.

However, CSL says it does not have the capacity to take on any more orders for the swine flu vaccine this year.

The company has a vaccine contract worth almost $220 million with the US Government, along with contracts for other countries including Australia.

Brian McNamee says the company has made boosting its production of the vaccine a high priority, but it is struggling.

"We're maxed out currently, unless we get a yield improvement, we're working diligently, we're trying to cheer on the eggs to make them sort of, to get the yields up, but they're a bit stuck at the moment," he said.

The company will pay a final dividend of 40 cents a share.

Its shares were down 1.3 per cent to $33.12 at 1:10pm (AEST).